In the HER2-negative subtype, the BCSS difference was more evident, with ER-positive/PR-positive breast cancers still manifesting the most preferred survival among the four groups and ER-positive/PR-negative breast cancers showing a better outcome than ER-negative/PR-positive ones. This evidence concerns the gene ESR1 and breast carcinoma.